HA
REGN icon

Halsey Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Halsey Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$8.76M Buy
31,560
+2,413
+8% +$714K 1.39% 30
2019
Q2 		$9.12M Buy
29,147
+10,408
+56% +$3.47M 1.63% 26
2019
Q1 		$7.7M Sell
18,739
-80
-0.4% -$32.9K 1.26% 33
2018
Q4 		$7.03M Buy
18,819
+811
+5% +$297K 1.33% 31
2018
Q3 		$7.28M Sell
18,008
-272
-1% -$104K 1.29% 31
2018
Q2 		$6.31M Buy
18,280
+1,681
+10% +$526K 1.22% 33
2018
Q1 		$5.72M Buy
16,599
+252
+2% +$87.6K 1.01% 35
2017
Q4 		$6.15M Buy
16,347
+1,266
+8% +$513K 1.05% 35
2017
Q3 		$6.74M Buy
15,081
+6,458
+75% +$3.07M 1.33% 33
2017
Q2 		$4.24M Buy
+8,623
New +$3.77M 0.87% 36

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Halsey Associates's REGN Position: Q3 2019 in Review

Halsey Associates increased its Regeneron Pharmaceuticals (REGN) stake by 8.3% in Q3 2019, buying an estimated $714K and bringing the position to 31,560 shares worth $8.76M. The position accounts for 1.39% of the portfolio, ranked #30.

Halsey Associates first reported a position in REGN in Q2 2017 and has held it in 10 quarters since. The position peaked at $9.12M in Q2 2019. 632 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

  • Halsey Associates held 31,560 shares of Regeneron Pharmaceuticals worth $8.76M as of Q3 2019.
  • Halsey Associates bought 2,413 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $714K.
  • Regeneron Pharmaceuticals made up 1.39% of Halsey Associates's portfolio in Q3 2019, its #30 holding.
  • Halsey Associates first reported a position in Regeneron Pharmaceuticals in Q2 2017 and has held it in 10 quarters since.
  • Halsey Associates's Regeneron Pharmaceuticals position peaked at $9.12M in Q2 2019.
  • 632 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Halsey Associates's 13F filing for Q3 2019, filed 15 Nov 2019.